Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma

British Journal of Haematology

Volumn 118, Issue 3, 2002, Pages 799-808

  Sun, Qi ^a   Burton, Robert ^a   Reddy, Vishnu ^c   Lucas, Kenneth G ^a,b,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

AIDS; EBV lymphoma; Hodgkin's disease; Immunotherapy; Organ transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; LEUKOCYTE ANTIGEN; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE IMMUNOTHERAPY; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; HLA MATCHING; HODGKIN DISEASE; HUMAN; LYMPH NODE; MALE; NONHODGKIN LYMPHOMA; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROLYMPHOCYTE; SYMPTOM; TREATMENT OUTCOME;

CELL CULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; LYMPHOMA; LYMPHOMA, AIDS-RELATED; ORGAN TRANSPLANTATION; PILOT PROJECTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036037324     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03683.x     Document Type: Article

References (46)

1. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low grade or follicular non-Hodgkin's lymphoma
2. Detection of Epstein-Barr viral genomes in lymph nodes of Hodgkin's disease patients
3. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation
4. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes
5. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
6. Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats
7. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - A 6-year update
8. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation
9. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells
10. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children
11. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival
12. Molecular biology of Epstein-Barr virus
13. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
14. Cord blood mononuclear cell transformation assay for screening for the presence of Epstein-Barr virus
15. A Phase I-II Trial to examine the toxicity of CMV and EBV specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34 selected/T cell depleted stem cell transplants
16. Rituximab in indolent lymphoma: The single-agent pivotal trial
17. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody
18. Epstein-Barr virus and its replication
19. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis
20. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
21. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors
22. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
23. The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients
24. HIV-associated non-Hodgkin's lymphomas: Clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors
25. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
26. Hodgkin's disease in patients with previous infectious mononucleosis: 30 Years' experience
27. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
28. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
29. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma
30. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated therapy of EBV+ Hodgkin's disease
31. Increased frequency of post transplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone
32. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
33. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142 - Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor
34. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65
35. B-lymphoblastoid cell lines as efficient antigen-presenting cells to elicit CD8+ T cell responses to a cytomegalovirus antigen
36. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
37. Aggressive treatment for postcardiac transplant lymphoproliferation
38. Limiting dilution assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single-hit Poisson model
39. Long-term survival of patients with HIV-related systemic non-Hodgkin's lymphomas
40. The Epstein-Barr virus and the immune system
41. Detection of Epstein-Barr virus DNA in Reed-Sternberg cells of Hodgkin's disease using the polymerase chain reaction and in situ hybridization
42. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats
43. Gene analysis and Epstein-Barr viral genome studies of Hodgkin's disease
44. Epstein-Barr viral DNA in tissues of Hodgkin's disease
45. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease
46. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study